Fractyl Health, Inc. Common Stock
GUTSFractyl Health, Inc. is a clinical-stage biotech company focused on developing transformative treatments for metabolic and gastrointestinal diseases. Known for its innovative approach to advancing therapies targeting conditions like type 2 diabetes and other metabolic disorders, the company emphasizes minimally invasive procedures and novel technologies to improve patient outcomes.
Company News
The global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaà Bio is producing...
Fractyl Health will call its outstanding Tranche A Common Stock Purchase Warrants, allowing holders to exercise at $1.05 per share until December 30, 2025, potentially raising $17.9 million in gross proceeds.
Fractyl Health reported positive 6-month clinical results showing patients maintained stable weight after a single Revita procedure following GLP-1 drug discontinuation, with minimal weight change and promising metabolic control.
Fractyl Health's CEO, Dr. Harith Rajagopalan, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, discussing the company's metabolic therapeutics approach to treating obesity and type 2 diabetes.
Fractyl Health, a metabolic therapeutics company, will report its Q3 2025 financial results and provide business updates on November 12, 2025, focusing on innovative treatments for obesity and type 2 diabetes.
